drugset / Trial / NCT04674956
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Aim：Evaluate the efficiency and safety of anti-PD1 antibody (Camrelizumab) combined with Paclitaxel(Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. Drug information： * anti-PD1 antibody (Camrelizumab) * AG regimens：the standard first-line regimens for metastatic pancreatic cancer.
Timeline
- Start
- 2021-03-04
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 125 mg/m2 | — |